Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

This study is testing whether giving immunotherapy (tislelizumab) combined with chemotherapy before surgery leads to better outcomes than going straight to surgery in people with resectable head and neck cancer. Researchers want to see if "priming" the immune system before surgery improves survival and cure rates. **You may be eligible if...** - You are 18–79 years old - You have confirmed head and neck squamous cell cancer, stage III or IVA, that can be surgically removed - You are in good physical condition - You have never received immunotherapy before (no prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 drugs) - Your organ function (kidneys, liver) is adequate based on recent blood tests **You may NOT be eligible if...** - You have received prior immunotherapy for your cancer - You are 80 or older - Your cancer cannot be surgically removed - Your overall health is too poor to tolerate chemotherapy or surgery Talk to your doctor to see if this trial is right for you.